These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10851492)

  • 1. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T ; Canossi A; Maccarone D; Papola F; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Dec; 12(6):385-93. PubMed ID: 10851492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T; Adorno D
    Cancer Biother Radiopharm; 2006 Oct; 21(5):488-505. PubMed ID: 17105421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T; Canossi A; Di Rocco M; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):373-83. PubMed ID: 10851498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
    Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU
    Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Cencioni S; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):257-64. PubMed ID: 10851473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
    Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
    J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence.
    Kato M; Ito Y; Kobayashi S; Isono K
    Cancer; 1996 Apr; 77(8 Suppl):1729-35. PubMed ID: 8608570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of immunological evaluation in colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Maccarone D; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):355-61. PubMed ID: 10851496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation.
    Kim H; Yang XL; Rosada C; Hamilton SR; August JT
    Arch Biochem Biophys; 1994 May; 310(2):504-7. PubMed ID: 7513984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological directives for biotherapy improvement in the treatment of colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Apr; 11(2):113-8. PubMed ID: 10851527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
    Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
    Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma.
    Williams AC; Browne SJ; Yeudal WA; Paterson IC; Marshall CJ; Lane DP; Paraskeva C
    Oncogene; 1993 Nov; 8(11):3063-72. PubMed ID: 8414507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic alterations of human colorectal cancer].
    Suzuki T; Ishioka C; Gamo M; Niitani T; Shimodaira H; Kanbe M; Yamazaki T; Yusa Y; Kanamaru R
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):343-50. PubMed ID: 8109990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
    Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
    Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.